3/23/15 ( CYBR )
The ongoing series of well-publicized cyber attacks on large companies is causing businesses to become more concerned about protecting themselves from this threat. Advanced IT security company CyberArk (CYBR ) has "massive," growth potential
Celladon Shares May Have Upside to $70
We are initiating coverage of Celladon with a Buy rating and price target of $70.
The developer of gene therapy for heart failure to announce pivotal trial results.
The total annual cost of treating heart failure today is $39 billion in the U.S. alone. By virtue of investment in Celladon, a number of pharmaceutical companies have a front row seat to evaluate the significanceofCUPID 2. We anticipate a licensing or a merger and acquisition (M&A) transaction, if results are promising